

Message

From: Nam, Ed [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A2653F1DDD59470688BA557DD84D9690-NAM, ED]
Sent: 7/26/2018 6:48:03 PM
To: Stepp, Cathy [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=befdafc0fa1a425eae232f60ad9bda1d-Stepp, Cath]; Thiede, Kurt [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3cc09fac5acc4ce1ba689fb2ce70d459-Thiede, Kur]; Payne, James [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=61b3204a683041079512b122c580a569-Payne, Jame]
CC: Nelson, Leverett [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2229a07c2cb442b182332d9dcc325f13-LNelson]; Kelley, Jeff [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e154fa5a5f744c70aa3da58e3f87aabe-JKelley]; Ballotti, Doug [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bb4ccaa2d889499b84d7d4784c0d160a-DBallott]; Newton, Cheryl [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ae08c2f1c2304a61bf7c01de62f35dbf-Cenewton]; Short, Thomas [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=06e6366deab241b7b204d2d8415f9cbf-TShort]; Furey, Eileen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5aaa3a0ee58047d983897c53c1eb283e-EFurey]; Siegel, Kathryn [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f57a52efead9497cb582b11b8c85f09f-KSiege02]
Subject: RE: ATSDR Letter Health Consultation for Sterigenics

Cathy, Kurt, Jim,

I just spoke with Mark Johnson of ATSDR. He informed me that their normal process is to clear these kinds of letter up the chain and (after approval) post it on their website. However the timing of that is somewhat flexible. So it looks like it doesn't have to be next week. He is amenable to coordinating the release with us, though he agrees that we don't want to hold off too long.

I also told him that we would like to be part of the coordination with the follow-on IDPH study (mentioned in the recommendations at the end of the letter). We would presumably bring IEPA into it as well. This study would take some time to conduct, so Mark is eager to get it started. I will bring this up on my call with OAQPS as soon as I can and hopefully report back on Monday.

Thanks,
-Ed

From: Johnson, Mark
Sent: Thursday, July 26, 2018 8:34 AM
To: Nam, Ed <nam.ed@epa.gov>; Siegel, Kathryn <siegel.kathryn@epa.gov>; Cain, Alexis <cain.alexis@epa.gov>; Bollweg, George <bollweg.george@epa.gov>
Cc: Colledge, Michelle <Colledge.Michelle@epa.gov>
Subject: ATSDR Letter Health Consultation for Sterigenics

Ed

Here is the ATSDR Letter Health Consultation for Sterigenics, prepared by Michelle Colledge, as requested by ARD. It has been cleared by our agency and has incorporated recent comments from ARD staff. Let me know if you have any questions.

We will be distributing this letter to our colleagues at the Illinois Department of Public Health. Feel free to share with your agency partners.

Mark

Mark D. Johnson, PhD, DABT
Regional Director/Toxicologist
Agency for Toxic Substances and Disease Registry (ATSDR)
77 W. Jackson Blvd. Rm. 433
Chicago, IL 60604
Email: mdjohnson@cdc.gov
Office: 312-353-3436
Cell: 312-307-7415